Results 51 to 60 of about 347,205 (251)

Costs of vaccine delivery in the Gambia before and after, pentavalent and pneumococcal conjugate vaccine introductions.

, 2014
BACKGROUND: The Gambia introduced seven-valent pneumococcal conjugate vaccine (PCV) in August 2009 and switched to 13-valent PCV in April 2011. In April 2009 monovalent hepatitis B and combined Diphtheria-Tetanus-Pertussis and Haemophilus influenzae type
Lowe-Jallow, Y, Mackenzie, G, Atherly, D, Griffiths, UK, Boye, B, Usuf, E, Suraratdecha, C   +6 more
core   +1 more source

Haemophilus influenzae type b disease in the era of conjugate vaccines: Critical factors for successful eradication

, 2020
INTRODUCTION: Prior to implementation of Haemophilus influenzae type b (Hib)-conjugate vaccination programs in the 1990s, Hib was the commonest cause of bacterial meningitis in children aged 29,000 deaths worldwide in children aged
Nissen, Michael, Mukherjee, Piyali, Slack, Mary, Haas, Hervé, Mihalyi, Attila, Harrington, Lauriane, Esposito, Susanna   +6 more
core   +1 more source

Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease. [PDF]

, 2010
BACKGROUND: The 7-valent pneumococcal conjugate vaccine has been introduced in national immunisation programmes of most industrialised countries and recently in two African GAVI eligible countries (Rwanda and The Gambia). However the long term effects of
George, Robert, Robert George, Y.H. Choi, Miller, Elizabeth, Edmunds, John W., Elizabeth Miller, Melegaro, Alessia, Yoon Hong Choi, E. Miller, Choi, Yoon Hong, Gay, Nigel J, Edmunds, W John, Nigel J Gay, R. George, W John Edmunds, Alessia Melegaro, N.J. Gay, W.J. Edmunds, Gay, Nigel J., George Robert, Miller Elizabeth, Edmunds W John, Choi Yoon, Gay Nigel J, Melegaro Alessia   +24 more
core   +2 more sources

Myogenic Fusogen‐Engineered Lipid Nanoparticles Enhance mRNA Delivery in Skeletal Muscle

Advanced Functional Materials, EarlyView.
This study reports a biomimetic strategy of engineering full‐length Myomaker, a muscle‐specific fusogen, into lipid nanoparticles (LNPs) to harness the native myoblast fusion capability for skeletal muscle mRNA delivery. The resulting Mymk‐LNPs enhance transfection in differentiating myocytes and enable Cre‐mediated reporter activation in injured ...
Fangyu Zhang, Zhisheng Xu, Yaou Duan, Yehui Sun, Shiying Wu, Tao Long, Mateusz Durbacz, Li Zhang, Yufen Xiao, Yu‐Chung Pien, Erick D. Guerrero, Zeru Tian, Xu Wang, Pratima Basak, Sumanta Chatterjee, Ning Liu, Xiaochun Li, Eric N. Olson, Daniel J. Siegwart   +18 more
wiley   +1 more source

Planning for new health interventions for developing countries : an integrated strategy to prepare for malaria vaccines and lessons for future interventions [PDF]

, 2011
Historically, new health interventions have been developed primarily to address the needs of the wealthy in developed countries. Where drugs, vaccines, diagnostic tests and other interventions happened to address diseases prevalent in the developing ...
Brooks, Alan
core   +1 more source

A Holistic Platform Approach for Developing Robust Pulmonary mRNA Delivery: Integrating Novel Phenolic Acid‐Derived Ionizable Lipids and Device Engineering

Advanced Functional Materials, EarlyView.
An integrated pulmonary mRNA delivery platform combining novel biodegradable syringic acid‐derived ionizable lipids, design‐of‐experiments formulation optimization, and vibrating‐mesh nebulizer engineering enabled stable aerosolization and efficient lung delivery.
Neha Kaushal, Younan Ma, Asad Khanmohammed, Dipen Parande, Hanming Zhang, Saket Dolare, Juliet Chen, Apiwat Wangweerawong, Saswata Karmakar, Hongfeng Deng, Frank Koppenhagen, Shraddha Sharma, Eric Reyes, Sherry He, Lianne Boeglin, Caroline Woo, Azadeh Paksa, Ayed Allawzi, Anusha Dias, Gregory Troiano, Shrirang Karve, Frank DeRosa   +21 more
wiley   +1 more source

Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study [PDF]

, 2011
We investigated the effect of the 7-valent pneumococcal conjugate vaccine (PCV7) programme in England on serotype-specific carriage and invasive disease to help understand its role in serotype replacement and predict the impact of higher valency vaccines.
Andrews, Nick, George, Robert, Robert George, Miller, Elizabeth, Van Hoek, Albert Jan, Carmen Sheppard, George Robert, Miller Elizabeth, Van Hoek Albert Jan, Waight Pauline, Andrews Nick, Flasche Stefan, Nick Andrews, Stefan Flasche, Elizabeth Sheasby, Albert Jan, Van Hoek, Elizabeth Miller, Flasche, Stefan, Albert Jan Van Hoek, Sheppard, Carmen, Waight, Pauline, Sheasby, Elizabeth, Pauline Waight, Sheasby Elizabeth, Sheppard Carmen   +24 more
core   +4 more sources

State of pneumococcal vaccine immunity

Human Vaccines & Immunotherapeutics
Like the other invasive encapsulated bacteria, Streptococcus pneumoniae is also covered with a polysaccharide structure. Infants and elderly are most vulnerable to the invasive and noninvasive diseases caused by S. pneumoniae. Although antibodies against
Mustafa Akkoyunlu
doaj   +1 more source

Conjugate Vaccines and the Carriage of Haemophilus influenzae Type b

Emerging Infectious Diseases, 1996
Pharyngeal carriage of Haemophilus influenzae type b (Hib) is important in the transmission of Hib organisms, the pathogenesis of Hib disease, and the development of immunity to the bacterium.
Marina L. Barbour, D. Phil
doaj   +1 more source

A glycoconjugate of Haemophilus influenzae Type b capsular polysaccharide with tetanus toxoid protein: hydrodynamic properties mainly influenced by the carbohydrate [PDF]

, 2016
Three important physical properties which may affect the performance of glycoconjugate vaccines against serious disease are molar mass (molecular weight), heterogeneity (polydispersity), and conformational flexibility in solution.
Harding, Stephen E., Conrath, K., Almuntari, F., Almutairi, Fahad M., Duvivier, Pierre, Harding, S. E., Adams, G. G., Morris, Gordon, Duvivier, P., Morris, Gordon A., Abdelhameed, Ali Saber, Adams, Gary G., Abdelhameed, A. S., Conrath, Karel, GSK Vaccines, Rue de l’Institut 89, B-1330 Rixensart, Belgium   +14 more
core   +1 more source